Our results suggest that NEK1 contributes to ALS pathogenesis through the LOF mechanism, and HDAC6 inhibition provides an attractive therapeutic strategy for NEK1 variants associated ALS treatment. This evidence concerns the gene HDAC6 and amyotrophic lateral sclerosis.